000650 仁和药业
2026/09 - 九个月
人民幣(K¥)
与去年同期
比较
2025/12
人民幣(K¥)
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
营业总收入2,791,652-1.48%3,536,4224,074,8935,032,1465,153,215
减:营业总成本2,257,170-3.45%2,913,9533,362,2324,045,0634,208,237
    其中:营业成本1,773,158-1.56%2,229,2342,528,8813,164,0923,266,277
               财务费用452-38.57%393(10,312)(24,925)(23,065)
               资产减值损失(191)-277.45%(129,175)(113,320)(223,111)(68,739)
公允价值变动收益44,092-5,429.18%25,11716,03416,82822,115
投资收益20,632-46.17%83,43072,70259,26146,314
    其中:对联营企业和合营企业的投资收益(3,417)16.27%(3,569)(4,831)(915)1,803
营业利润601,176-2.56%665,212774,986898,635953,263
利润总额602,789-2.15%664,897774,618898,860953,540
减:所得税费用145,712-0.84%177,240208,033269,450241,997
净利润457,077-2.57%487,657566,586629,410711,542
减:非控股权益84,905-5.63%94,44984,67462,153137,112
股东净利润372,171-1.84%393,208481,912567,257574,430

市场价值指针
每股收益 (元) *0.266-1.85%0.2800.3500.4100.410
每股派息 (元) *0.051--0.1520.1500.2000.200
每股净资产 (元) *4.5570.44%4.5114.4104.2814.101
审计意见 #--标准的无保留意见标准的无保留意见标准的无保留意见标准的无保留意见
回页顶
备注: *未调整数据
#只提供简体内容